The FDA guidelines for the treatment of psoriasis using cyclosporine A: Are they adequate?

Cutis

Volumn 70, Issue 5, 2002, Pages 288-290

  Zackheim, Herschel S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DERMATOLOGICAL AGENT;

FOOD AND DRUG ADMINISTRATION; HUMAN; PSORIASIS; REVIEW; STANDARD; TIME; UNITED STATES;

CYCLOSPORINE; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 1842858964     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Physicians' Desk Reference: PDR 2002. 56th ed. Montvale, NJ: Medical Economics Co; 2002.
2. Grossman RM, Chevret S, Abi-Rached J. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623-629.
3. Lowe NJ, Wieder IM, Rosenbach A, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996;35:710-719.
4. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol. 1997;136:531-535.
5. Powles AV, Cook T, Hulme B, et al. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol. 1993;128:159-165.
6. Powles AV, Hardman CM, Porter WM, et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol. 1998;138:443-449.
7. Pei Y, Scholey JW, Katz A, et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis. 1994;23:528-536.
8. de Rie MA, Meinardi MM, Bos JD. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol. 1990;123:347-353.
9. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine emulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643-651.
10. Koo JY, Kadonaga JN, Wintroub BV, et al. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1992;26(5 pt 2):836-840.
11. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2:723-731.
12. Massouye I, Salamon D, Saurat J-H. B-cell lymphoma after cyclosporine for keratosis lichenoides chronica. Arch Dermatol. 1993;129:914-915.
13. Cliff S, Pettengell R, Gharge S, et al. B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis. Br J Dermatol. 1999;140:763-765.
14. Bagot M, Dubertret L. Lymphocytic infiltrates of the skin in association with cyclosporine therapy [letter]. J Am Acad Dermatol. 1992;26(2 pt 1):283.
15. Yamamoto T, Katayama I, Nishioka K. Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy. Dermatology. 1996;193:72-73.
16. Grossman RM, Maugee E, Dubertret L. Cervical intraepithelial neoplasia in a patient receiving long-term cyclosporin for the treatment of severe plaque psoriasis. Br J Dermatol. 1996;135:147-148.
17. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042-1045.
18. Anonymous. New human carcinogen named [news]. Lancet. 1998;351:1563.